Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Dcy636

Phase 1

Dcy636 is one of 7 therapeutic programs targeting Dermatitis, Atopic. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

6

Competitors

Pipeline

Status by Indication[2][1]

Indication

Dermatitis, AtopicRecruiting

Dermatitis, AtopicPhase 1

Recruiting

Competition

Competitive Landscape

8 competitors in Dermatitis, Atopic

#DrugCompanyPhaseTrials

Amlitelimab

Topical Corticosteroids

Topical Calcineurin Inhibitors

JNJ-95597528

Johnson & Johnson

Calcineurin Inhibitors

Dcy636

Oral Corticosteroids

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Dermatitis, Atopic

NCT07604324

Clinical

Trials by Indication[1]

Dermatitis, Atopic1 trial

A Two-part, Randomized, Participant- and Investigator-blinded, Placebo Controlled First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of DCY636 in a Single Ascending Dose Part in Healthy Participants and in a Multiple Dose Part in Participants With Moderate to Severe Atopic Dermatitis

Recruiting· Novartis logo

Novartis·Phase 1·NCT07604324·63 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dcy636. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Dcy636. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Novartis

Related News